ViiV Healthcare's Tivicay PD (dolutegravir) Receives the US FDA's Approval for Children Living with HIV
Shots:
- The approval is based on ongoing P1093 (NCT03016533) and ODYSSEY (PENTA20- NCT02259127) studies in pediatric patients aged 4 weeks to 18 years- while the second study involves 2L pediatric patients aged four weeks to 18 years
- The P1093 study was conducted by IMPAACT network in the USA- Brazil- Thailand- South Africa- Zimbabwe- Kenya and Tanzania and ODYSSEY by the PENTA network in Europe- South America- Thailand- Uganda- Zimbabwe- and South Africa
- Tivicay and Tivicay PD are a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used in combination with antiretroviral agents to treat HIV-1 infection in adults and in pediatric patients aged at least 4 weeks and weighing at least 3 kg
Ref: ViiV Healthcare | Image: Behance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com